You are here

CAR-T

Novartis says CAR-T cancer therapy works in second lymphoma type

Novartis says CAR-T cancer therapy works in second lymphoma type

BioPharma Dive

follicular lymphoma

Flag link:

FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population

FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population

MedCity News

diffuse large B-cell lymphoma

Flag link:

Gilead’s Kite gains some height after second CAR-T approval in US

Gilead’s Kite gains some height after second CAR-T approval in US

Pharmaforum

Gilead Sciences

Flag link:

Gilead’s Kite Pharma gets FDA nod for second CAR-T cell therapy

Gilead’s Kite Pharma gets FDA nod for second CAR-T cell therapy

MedCity News

Gilead Sciences

Flag link:

Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold

Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold

Fierce Biotech

Multiple Myeloma

Flag link:

Bayer-backed Century buys Empirica to create brain cancer CAR-Ts

Bayer-backed Century buys Empirica to create brain cancer CAR-Ts

Fierce Biotech

Century Therapeutics

Flag link:

Sana Biotechnology raises more than $700M for cell, gene therapy efforts

Sana Biotechnology raises more than $700M for cell, gene therapy efforts

MedCity News

Sana Biotechnology

Juno Therapeutics

Flag link:

Poseida Therapeutics guns again for IPO

Poseida Therapeutics guns again for IPO

Fierce Biotech

Poseida Therapeutics

Flag link:

Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online

Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online

Fierce Pharma

Gilead Sciences

drug manufacturing

Flag link:

ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama

ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama

Pharmaforum

Bristol-Myers Squibb

Flag link:

ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma

ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma

Fierce Biotech

Flag link:

CMS proposes 1.6% inpatient increase and new CAR-T cell therapy payment

CMS proposes 1.6% inpatient increase and new CAR-T cell therapy payment

Healthcare Finance News

Flag link:

Gilead, Kite pen natural killer pact with little-known Australian cell therapy player

Gilead, Kite pen natural killer pact with little-known Australian cell therapy player

Fierce Biotech

Gilead Sciences

natural killer cell therapies

Flag link:

Calling Gilead's CAR-T infringement 'willful,' judge enhances BMS' award to $1.2B

Calling Gilead's CAR-T infringement 'willful,' judge enhances BMS' award to $1.2B

Fierce Pharma

Gilead Sciences

Bristol-Myers Squibb

Flag link:

J&J inks Fate deal to move into allogeneic CAR therapies

J&J inks Fate deal to move into allogeneic CAR therapies

Fierce Biotech

Fate Therapeutics

drug development

Flag link:

Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb

Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb

Endpoints

Gilead Sciences

Bristol-Meyers Squibb

Juno Therapeutics

Flag link:

Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan

Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan

Pharmaceutical Business Review

axicabtagene ciloleucel

relapsed or refractory diffuse large B-cell lymphoma

Flag link:

Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T

Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T

Endpoints

Bristol-Meyers Squibb

Flag link:

AbbVie-backed Carisma's 'CAR-M' tech shrinks tumors in mouse models of ovarian cancer

AbbVie-backed Carisma's 'CAR-M' tech shrinks tumors in mouse models of ovarian cancer

Fierce Biotech

Carisma Therapeutics

Flag link:

J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO

J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO

Endpoints

Flag link:

Pages